Literature DB >> 18628432

Performance of amplified DNA in an Illumina GoldenGate BeadArray assay.

Julie M Cunningham1, Thomas A Sellers, Joellen M Schildkraut, Zachary S Fredericksen, Robert A Vierkant, Linda E Kelemen, Madhura Gadre, Catherine M Phelan, Yifan Huang, Jeffrey G Meyer, V Shane Pankratz, Ellen L Goode.   

Abstract

Whole genome amplification (WGA) offers a means to enrich DNA quantities for epidemiologic studies. We used an ovarian cancer study of 1,536 single nucleotide polymorphisms (SNPs) and 2,368 samples to assess performance of multiple displacement amplification (MDA) WGA using an Illumina GoldenGate BeadArray. Initial screening revealed successful genotyping for 93.4% of WGA samples and 99.3% of genomic samples, and 93.2% of SNPs for WGA samples and 96.3% of SNPs for genomic samples. SNP failure was predicted by Illumina-provided designability rank, %GC (P < or = 0.002), and for WGA only, distance to telomere and Illumina-provided SNP score (P < or = 0.002). Distance to telomere and %GC were highly correlated; adjustment for %GC removed the association between distance to telomere and SNP failure. Although universally high, per-SNP call rates were related to designability rank, SNP score, %GC, minor allele frequency, distance to telomere (P < or = 0.01), and, for WGA only, Illumina-provided validation class (P < 0.001). We found excellent concordance generally (>99.0%) among 124 WGA:genomic replicates, 15 WGA replicates, 88 replicate aliquots of the same WGA preparation, and 25 genomic replicates. Where there was discordance, it was across WGA:genomic replicates but limited to only a few samples among other replicates suggesting the introduction of error. Designability rank and SNP score correlated with WGA:genomic concordance (P < 0.001). In summary, use of MDA WGA DNA is feasible; however, caution is warranted regarding SNP selection and analysis. We recommend that biological SNP characteristics, notably distance to telomere and GC content (<50% GC recommended), as well as Illumina-provided metrics be considered in the creation of GoldenGate assays using MDA WGA DNA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18628432      PMCID: PMC2732190          DOI: 10.1158/1055-9965.EPI-07-2849

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  27 in total

1.  Comprehensive human genome amplification using multiple displacement amplification.

Authors:  Frank B Dean; Seiyu Hosono; Linhua Fang; Xiaohong Wu; A Fawad Faruqi; Patricia Bray-Ward; Zhenyu Sun; Qiuling Zong; Yuefen Du; Jing Du; Mark Driscoll; Wanmin Song; Stephen F Kingsmore; Michael Egholm; Roger S Lasken
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

2.  Quantitative evaluation by minisequencing and microarrays reveals accurate multiplexed SNP genotyping of whole genome amplified DNA.

Authors:  Lovisa Lovmar; Mona Fredriksson; Ulrika Liljedahl; Snaevar Sigurdsson; Ann-Christine Syvänen
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

3.  Multiple displacement amplification prior to single nucleotide polymorphism genotyping in epidemiologic studies.

Authors:  Gregory J Tranah; Pamela J Lescault; David J Hunter; Immaculata De Vivo
Journal:  Biotechnol Lett       Date:  2003-07       Impact factor: 2.461

4.  Two methods of whole-genome amplification enable accurate genotyping across a 2320-SNP linkage panel.

Authors:  David L Barker; Mark S T Hansen; A Fawad Faruqi; Diane Giannola; Orlando R Irsula; Roger S Lasken; Martin Latterich; Vladimir Makarov; Arnold Oliphant; Jonathon H Pinter; Richard Shen; Irina Sleptsova; William Ziehler; Eric Lai
Journal:  Genome Res       Date:  2004-05       Impact factor: 9.043

5.  Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification.

Authors:  J Guillermo Paez; Ming Lin; Rameen Beroukhim; Jeffrey C Lee; Xiaojun Zhao; Daniel J Richter; Stacey Gabriel; Paula Herman; Hidefumi Sasaki; David Altshuler; Cheng Li; Matthew Meyerson; William R Sellers
Journal:  Nucleic Acids Res       Date:  2004-05-18       Impact factor: 16.971

6.  Single-nucleotide-polymorphism genotyping for whole-genome-amplified samples using automated fluorescence correlation spectroscopy.

Authors:  Makoto Bannai; Kaori Higuchi; Tamao Akesaka; Masako Furukawa; Megumi Yamaoka; Kazuhisa Sato; Katsushi Tokunaga
Journal:  Anal Biochem       Date:  2004-04-15       Impact factor: 3.365

7.  Genome-wide single-nucleotide polymorphism arrays demonstrate high fidelity of multiple displacement-based whole-genome amplification.

Authors:  Mladen V Tzvetkov; Christian Becker; Bettina Kulle; Peter Nürnberg; Jürgen Brockmöller; Leszek Wojnowski
Journal:  Electrophoresis       Date:  2005-02       Impact factor: 3.535

8.  Effects of electron-beam irradiation on whole genome amplification.

Authors:  Andrew W Bergen; Ying Qi; Kashif A Haque; Robert A Welch; Montserrat Garcia-Closas; Stephen J Chanock; Jim Vaught; Philip E Castle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-04       Impact factor: 4.254

9.  Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer.

Authors:  Thomas A Sellers; Yifan Huang; Julie Cunningham; Ellen L Goode; Rebecca Sutphen; Robert A Vierkant; Linda E Kelemen; Zachary S Fredericksen; Mark Liebow; V Shane Pankratz; Lynn C Hartmann; Jeff Myer; Edwin S Iversen; Joellen M Schildkraut; Catherine Phelan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-02       Impact factor: 4.254

10.  Genotyping human arylamine N-acetyltransferase type 1 (NAT1): the identification of two novel allelic variants.

Authors:  M A Payton; E Sim
Journal:  Biochem Pharmacol       Date:  1998-02-01       Impact factor: 5.858

View more
  22 in total

1.  Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk.

Authors:  Ellen L Goode; Kristin L White; Robert A Vierkant; Catherine M Phelan; Julie M Cunningham; Joellen M Schildkraut; Andrew Berchuck; Melissa C Larson; Brooke L Fridley; Janet E Olson; Penelope M Webb; Xiaoqing Chen; Jonathan Beesley; Georgia Chenevix-Trench; Thomas A Sellers
Journal:  Mol Carcinog       Date:  2010-12-28       Impact factor: 4.784

2.  Associations between maternal genotypes and metabolites implicated in congenital heart defects.

Authors:  Shimul Chowdhury; Charlotte A Hobbs; Stewart L MacLeod; Mario A Cleves; Stepan Melnyk; S Jill James; Ping Hu; Stephen W Erickson
Journal:  Mol Genet Metab       Date:  2012-09-27       Impact factor: 4.797

3.  MTHFR polymorphisms in relation to ovarian cancer risk.

Authors:  Kathryn L Terry; Shelley S Tworoger; Ellen L Goode; Margaret A Gates; Linda Titus-Ernstoff; Linda E Kelemen; Thomas A Sellers; Susan E Hankinson; Daniel W Cramer
Journal:  Gynecol Oncol       Date:  2010-11       Impact factor: 5.482

Review 4.  Genome-wide scans of genetic variants for psychophysiological endophenotypes: a methodological overview.

Authors:  William G Iacono; Stephen M Malone; Uma Vaidyanathan; Scott I Vrieze
Journal:  Psychophysiology       Date:  2014-12       Impact factor: 4.016

5.  Interpretation of custom designed Illumina genotype cluster plots for targeted association studies and next-generation sequence validation.

Authors:  Elizabeth A Tindall; Desiree C Petersen; Stina Nikolaysen; Webb Miller; Stephan C Schuster; Vanessa M Hayes
Journal:  BMC Res Notes       Date:  2010-02-22

6.  Risk of ovarian cancer and inherited variants in relapse-associated genes.

Authors:  Abraham Peedicayil; Robert A Vierkant; Lynn C Hartmann; Brooke L Fridley; Zachary S Fredericksen; Kristin L White; Elaine A Elliott; Catherine M Phelan; Ya-Yu Tsai; Andrew Berchuck; Edwin S Iversen; Fergus J Couch; Prema Peethamabaran; Melissa C Larson; Kimberly R Kalli; Matthew L Kosel; Vijayalakshmi Shridhar; David N Rider; Mark Liebow; Julie M Cunningham; Joellen M Schildkraut; Thomas A Sellers; Ellen L Goode
Journal:  PLoS One       Date:  2010-01-27       Impact factor: 3.240

7.  Assessing the utility of whole-genome amplified serum DNA for array-based high throughput genotyping.

Authors:  Kristine L Bucasas; Gagan A Pandya; Sonal Pradhan; Robert D Fleischmann; Scott N Peterson; John W Belmont
Journal:  BMC Genet       Date:  2009-12-18       Impact factor: 2.797

8.  In vitro vs in silico detected SNPs for the development of a genotyping array: what can we learn from a non-model species?

Authors:  Camille Lepoittevin; Jean-Marc Frigerio; Pauline Garnier-Géré; Franck Salin; María-Teresa Cervera; Barbara Vornam; Luc Harvengt; Christophe Plomion
Journal:  PLoS One       Date:  2010-06-09       Impact factor: 3.240

9.  Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer.

Authors:  Kristin L White; Robert A Vierkant; Catherine M Phelan; Brooke L Fridley; Stephanie Anderson; Keith L Knutson; Joellen M Schildkraut; Julie M Cunningham; Linda E Kelemen; V Shane Pankratz; David N Rider; Mark Liebow; Lynn C Hartmann; Thomas A Sellers; Ellen L Goode
Journal:  BMC Cancer       Date:  2009-06-06       Impact factor: 4.430

10.  Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.

Authors:  J M Cunningham; R A Vierkant; T A Sellers; C Phelan; D N Rider; M Liebow; J Schildkraut; A Berchuck; F J Couch; X Wang; B L Fridley; A Gentry-Maharaj; U Menon; E Hogdall; S Kjaer; A Whittemore; R DiCioccio; H Song; S A Gayther; S J Ramus; P D P Pharaoh; E L Goode
Journal:  Br J Cancer       Date:  2009-09-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.